Advice
in the absence of a submission from the holder of the marketing authorisation
anakinra (Kineret®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including:
• Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)
• Muckle-Wells Syndrome (MWS)
• Familial Cold Autoinflammatory Syndrome (FCAS)
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice91KB (PDF)
Medicine details
- Medicine name:
- anakinra (Kineret)
- SMC ID:
- 1116/15
- Indication:
- Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including:
- Pharmaceutical company
- Swedish Orphan
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 December 2015